• 1
    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case–control study. Lancet 2005; 365 (9458): 47581.
  • 2
    Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364 (9450): 20219.
  • 3
    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092102.
  • 4
    Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma. N Engl J Med 2005; 352: 107180.
  • 5
    Singh G, Mithal A, Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. Ann Rheum Dis 2005; 64 (Suppl. III): 85.
  • 6
    Sturkenboom MCJM, Dieleman J, Verhamme K, Straus S, Hoeven-Borgman MV, Van Der Lei J. Cardiovascular events during use of COX-2 selective and non-selective NSAIDs. Pharmacoepidemiol Drug Saf 2005; 14: S57.
  • 7
    Hippsley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case control analysis. BMJ 2005; 330: 136672.
  • 8
    Johnsen SP, Larson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, Sorensen HT. Risk of hospitalisation for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs. Arch Intern Med 2005; 165: 97884.
  • 9
    Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142: 4819.
  • 10
    Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 15764.
  • 11
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 206873.
  • 12
    Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A. Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163: 4816.
  • 13
    Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. Cyclo-oxygenase-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 10713.
  • 14
    Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins D. Selective cyclo-oxygenase-2 inhibition and cardiovascular effects. Arch Intern Med 2005; 165: 1816.
  • 15
    Kerr SJ, Mant A, Horn FE, McGeechan K, Sayer GP. Lessons from early large-scale adoption of celecoxib and rofecoxib by general practitioners. Med J Aust 2003; 179: 4037.
  • 16
    Pharmaceutical Benefits Schedule Item Statistics. Health Insurance Commission of Australia. Available at Last accessed 9 January 2006.
  • 17
    Schlienger RG, Jick H, Meier CR. Use of non-steroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002; 54: 32733.
  • 18
    Solomon DH, Glynn RJ, Levin R, Avorn J. Non-steroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099104.
  • 19
    PRISM Study Group. Platelet receptor inhibition in ischaemic syndrome management in patients limited by unstable signs and symptoms. (PRISM-PLUS study investigators). New Engl J Med 1998; 338: 148897.
  • 20
    Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and cyclo-oxygenase-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by cyclo-oxygenase-2. J Immunol 2001; 167: 28318.
  • 21
    Penglis PS, Cleland LG, Demasi M, Caughey GE, James MJ. Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol 2000; 165: 160511.
  • 22
    Bolli R, Shinmura K, Tang XL, Kodani E, Xuan YT, Guo Y, Dawn B. Discovery of a new function of cyclooxygenase (COX)-2: cyclo-oxygenase-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 2002; 55: 50619.
  • 23
    Shinmura K, Kodani E, Dawn B, Tang XL, Bolli R. Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits. J Am Coll Cardiol 2003; 41: 118394.
  • 24
    Cippollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability. Circulation 2001; 104: 9217.
  • 25
    Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor deficient mice. Circulation 2002; 105: 181623.
  • 26
    Rott D, Zhu J, Burnett MS, Zhou YF, Zalles-Ganley A, Ogunmakinwa J, Epstein SE. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol 2003; 41: 18129.
  • 27
    Bea F, Blessing E, Bennett BJ, Kuo CC, Campbell LA, Kreuzer J, Rosenfeld ME. Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res 2003; 60: 198204.
  • 28
    Egan KM, Wang M, Lucitt MB, Zukas AM, Pure E, Lawson JA, Fitzgerald GA. Cyclooxygenases, thromboxane and atherosclerosis – plaque destabilisation by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111: 33442.
  • 29
    Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A, Identification of New Elements of Plaque Stability (INES) Study Group. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004; 291: 22218.
  • 30
    Hill MR, Papafili A, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002; 22: 16316.
  • 31
    Beauchamp GK, Keast RSJ, Morel D, Lin J, Pika J, Han Q, Lee CH, Smith AB, Breslin PAS. Ibuprofen-like activity in extra-virgin olive oil. Nature 2005; 437: 456.